AnaptysBio (ANAB) Stock Forecast & Price Target $60.22 +0.45 (+0.74%) As of 03:18 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AnaptysBio - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 13 Analyst RatingsSell1Hold1Buy11 Based on 13 Wall Street analysts who have issued ratings for AnaptysBio in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 1 has given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for ANAB. Consensus Price Target $79.1831.50% Upside According to the 13 analysts' twelve-month price targets for AnaptysBio, the average price target is $79.18. The highest price target for ANAB is $100.00, while the lowest price target for ANAB is $50.00. The average price target represents a forecasted upside of 31.50% from the current price of $60.22. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for ANAB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for AnaptysBio and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANAB Analyst Ratings Over TimeTypeCurrent Forecast5/20/25 to 5/20/261 Month Ago4/20/25 to 4/20/263 Months Ago2/19/25 to 2/19/261 Year Ago5/20/24 to 5/20/25Strong Buy1 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)Buy10 Buy rating(s)9 Buy rating(s)9 Buy rating(s)5 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)4 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price Target$79.18$80.10$66.89$35.88Forecasted Upside31.50% Upside57.21% Upside20.61% Upside70.02% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy ANAB Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ANAB Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table AnaptysBio Stock vs. The CompetitionTypeAnaptysBioMedical CompaniesBroader MarketConsensus Rating Score 2.85 2.29 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside32.48% Upside1,742.64% Upside17.79% UpsideNews Sentiment RatingNeutral NewsSee Recent ANAB NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/15/2026 Leerink Partners2 of 5 starsDavid RisingerNot RatedSet Target$90.00+43.38%5/13/2026 Weiss RatingsNot Rated DowngradeSell (D-) ➝ Sell (E+)5/13/2026 UBS Group4 of 5 starsMichael YeeNot RatedBoost TargetBuy$60.00 ➝ $76.00+15.89%5/13/2026 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEtzer DaroutSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$63.00 ➝ $75.00+14.36%5/4/2026 Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeHold ➝ Strong-Buy5/4/2026 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingYasmeen RahimiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$95.00 ➝ $93.00+33.90%3/30/2026 HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEmily BodnarSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$66.00+14.98%3/25/2026 Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeHold3/12/2026 WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMartin FanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOutperform$60.00 ➝ $75.00+21.38%3/5/2026 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAlex ThompsonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$56.00 ➝ $85.00+40.38% Get the Latest News and Ratings for ANAB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter. 12/18/2025 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingYatin SunejaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy11/5/2025 Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDerek ArchilaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$51.00 ➝ $81.00+124.20%7/24/2025 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAnupam RamaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$42.00 ➝ $80.00+197.34%3/26/2025 Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingBuy2/4/2025 Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndy ChenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOutperform$25.00+50.06%12/2/2024 BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJulian HarrisonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ NeutralAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:19 PM ET. ANAB Forecast - Frequently Asked Questions What is AnaptysBio's forecast for 2026? According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for AnaptysBio is $79.18, with a high forecast of $100.00 and a low forecast of $50.00. Should I buy or sell AnaptysBio stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There is currently 1 sell rating, 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ANAB shares. Does AnaptysBio's stock price have much upside? According to analysts, AnaptysBio's stock has a predicted upside of 31.50% based on their 12-month stock forecasts. Has AnaptysBio been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, AnaptysBio's stock had 2 upgrades and 1 downgrade by analysts. What analysts cover AnaptysBio? AnaptysBio has been rated by research analysts at Barclays, HC Wainwright, Leerink Partners, Piper Sandler, Stifel Nicolaus, Truist Financial, UBS Group, Wedbush, Weiss Ratings, and Zacks Research in the past 90 days. Do Wall Street analysts like AnaptysBio more than its competitors? Analysts like AnaptysBio more than other "medical" companies. The consensus rating for AnaptysBio is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ANAB compares to other companies. Stock Forecasts and Research Tools Related Companies Qiagen Stock Forecast Kymera Therapeutics Stock Forecast Mirum Pharmaceuticals Stock Forecast Spyre Therapeutics Stock Forecast TG Therapeutics Stock Forecast Protagonist Therapeutics Stock Forecast CG Oncology Stock Forecast Lantheus Stock Forecast Rhythm Pharmaceuticals Stock Forecast PTC Therapeutics Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With AnaptysBio RecommendationsWall Street ZenLeerink PartnersBarclaysUBS GroupWeiss RatingsPiper SandlerZacks ResearchHC WainwrightTruist FinancialWedbushStifel NicolausGuggenheimWells Fargo & CompanyJPMorgan Chase & Co. This page (NASDAQ:ANAB) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
